SCHEMBL4798713

SCHEMBL4798713

O=C(O)c1ccc(OCCCO/N=C/c2cc3ccccc3n2Cc2ccccc2)cc1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 9/20 0.43
PLA2G2A P14555 1/20 0.42
MAOA P21397 3/20 0.42
CCR2 P41597 2/20 0.42
MCL1 Q07820 3/20 0.40
PLA2G4A P47712 1/20 0.39
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38
MAPT P10636 1/20 0.38
XBP1 P17861 1/20 0.38
RAB9A P51151 1/20 0.38
UBE2I P63279 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
SAE1 Q9UBE0 1/20 0.38
UBA2 Q9UBT2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4798722 1.00 MAOB (0.43) MAOBPLA2G2AMAOACCR2MCL1
SCHEMBL4798109 0.91 MAOB (0.42) MAOBPLA2G2AMAOACCR2MCL1
SCHEMBL4798124 0.91 MAOB (0.42) MAOBPLA2G2AMAOACCR2MCL1
SCHEMBL4800762 0.79 ALDH1A1 (0.50) PLA2G2AMEN1ALDH1A1LMNAPOLB
SCHEMBL4800748 0.79 ALDH1A1 (0.50) PLA2G2AMEN1ALDH1A1LMNAPOLB
SCHEMBL4797873 0.77 CCR2 (0.45) CCR2ALDH1A1PPARG
SCHEMBL4797886 0.77 CCR2 (0.45) CCR2ALDH1A1PPARG
SCHEMBL4800513 0.72 MAPT (0.52) PLA2G2AMEN1NPC1ALDH1A1LMNA
SCHEMBL4798983 0.72 MAPT (0.52) PLA2G2AMEN1NPC1ALDH1A1LMNA
SCHEMBL4799000 0.72 MAPT (0.52) PLA2G2AMEN1NPC1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7342039-B2 Substituted indole oximes WYETH (US) 2008-03-11 US claimed
US-20050119326-A1 Substituted aryloximes WYETH (US) 2005-06-02 US claimed
US-7342039-B2 Substituted indole oximes WYETH (US) 2008-03-11 US disclosed
EP-1667670-A1 4-(1H-INDOL-3-YL-METHYLIDENEAMINOXY-PROPOXY)-BENZOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIREMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS Wyeth (US) 2006-06-14 EP disclosed
US-20050119326-A1 Substituted aryloximes WYETH (US) 2005-06-02 US disclosed
WO-2005030192-A1 4- (1H-INDOL-3-YL-METHYLIDENEAMINOXY-PROPOXY) -BENZIOC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIRMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS WYETH (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119326-A1 Substituted aryloximes IDO2, TDO2, IDO1 MAOB 10/4885PLA2G2A 2434/4885MAOA 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.